HCM.US HUTCHMED DRC

Healthcare Pharmaceuticals USA Stocks
14.90 USD
Close of Nov 15, 2026
9.77 16.33
Market cap
USD 2.59B
P/E
149.0x
P/B
2.05x
ROE
2.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is HCM.US undervalued?

Graham number

The Graham number of HUTCHMED DRC cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

HUTCHMED DRC fundamental analysis

No fundamental analysis for HUTCHMED DRC yet.

HUTCHMED DRC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About HUTCHMED DRC

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), …

Full company profile